Your browser doesn't support javascript.
loading
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells.
Waarts, Michael R; Mowla, Shoron; Boileau, Meaghan; Martinez Benitez, Anthony R; Sango, Junya; Bagish, Maya; Fernandez-Maestre, Ines; Shan, Yufan; Eisman, Shira E; Park, Young C; Wereski, Matthew; Csete, Isabelle; O'Connor, Kavi; Romero-Vega, Angelica C; Miles, Linde A; Xiao, Wenbin; Wu, Xiaodi; Koche, Richard P; Armstrong, Scott A; Shih, Alan H; Papapetrou, Eirini P; Butler, Jason M; Cai, Sheng F; Bowman, Robert L; Levine, Ross L.
Afiliação
  • Waarts MR; Memorial Sloan Kettering Cancer Center, NYC, United States.
  • Mowla S; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Boileau M; Dana-Farber Cancer Institute, United States.
  • Martinez Benitez AR; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Sango J; Memorial Sloan Kettering Cancer Center, United States.
  • Bagish M; Memorial Sloan Kettering Cancer Center, United States.
  • Fernandez-Maestre I; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Shan Y; Dana-Farber Cancer Institute, United States.
  • Eisman SE; Columbia University Medical Center, New York, United States.
  • Park YC; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Wereski M; Memorial Sloan Kettering Cancer Center, United States.
  • Csete I; Memorial Sloan Kettering Cancer Center, United States.
  • O'Connor K; MSKCC, New York, New York, United States.
  • Romero-Vega AC; Memorial Sloan Kettering Cancer Center, New York, New York, United States.
  • Miles LA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Xiao W; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Wu X; Memorial Sloan Kettering Cancer Center, United States.
  • Koche RP; Memorial Sloan Kettering Cancer Center, New York, United States.
  • Armstrong SA; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, United States.
  • Shih AH; Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Papapetrou EP; Icahn School of Medicine at Mount Sinai, New York, United States.
  • Butler JM; Weill Cornell Medicine, New York, NY, United States.
  • Cai SF; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Bowman RL; University of Pennsylvania, Philadelphia, PA, United States.
  • Levine RL; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Cancer Discov ; 2024 May 31.
Article em En | MEDLINE | ID: mdl-38819218
ABSTRACT
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been hindered by the lack of an ex vivo platform amenable for studying primary hematopoietic stem and progenitor cells (HSPCs). Here, we utilize an ex vivo co-culture system of HSPCs with bone marrow endothelial cells to perform CRISPR/Cas9 screens in mutant HSPCs. Our data reveal that loss of the histone demethylase family members Kdm3b and Jmjd1c specifically reduces the fitness of Idh2- and Tet2-mutant HSPCs. Kdm3b loss in mutant cells leads to decreased expression of critical cytokine receptors including Mpl, rendering mutant HSPCs preferentially susceptible to inhibition of downstream JAK2 signaling. Our study nominates an epigenetic regulator and an epigenetically regulated receptor signaling pathway as genotype-specific therapeutic targets and provides a scalable platform to identify genetic dependencies in mutant HSPCs.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Discov Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Discov Ano de publicação: 2024 Tipo de documento: Article